Anticancer Drug Discovery and Development
The marked contribution of molecular oncology within the past three decades has revealed that the multistage process of cancer growth and progression is attributable to the accumulation of genetic and epigenetic alterations. Malignant carcinomas display genetic alterations in multiple oncogenes and tumor suppressor genes, harbor epigenetic modifications that result in altered expression of several genes and contain chromosomal alterations, including aneuploidy and loss of heterozigosity (Vogelstein and Kinzler 1993; Lengauer, Kinzler, and Vogelstein 1998).
KeywordsNuclear Magnetic Resonance Drug Discovery Virtual Screening Target Modulation Drug Development Process
Unable to display preview. Download preview PDF.
- Dalvit, C., Flocco, M., Veronesi, M. and Stockman, B. I. (2002) Fluorine-NMR competition binding experiments for high-throughput screening of large compound mixtures. Comb. Chem. & HTS. 5, 605–611.Google Scholar
- Sager, J. A. and Lengauer, C. (2003) New paradigms for cancer drug discovery? Canc. Biol. & Ther. 2, 178–181.Google Scholar
- Suggitt, M. and Bibby, M. C. (2005) Fifty years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Can. Res. (11) 971–981.Google Scholar
- Trosset, J. Y., Dalvit C., Knapp, S., Fasolini M., Veronesi, M., Mantegani S., Gianellini M., Catana C., Sundström M., Stouten P. F. W. and Moll J. K. (2006) Inhibition of protein-protein interactions: the discovery of drug-like beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 64, 60–67.PubMedCrossRefGoogle Scholar